We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Rhys
Morgan
rhys.morgan@sussex.ac.uk
Dr
Rhys
Morgan
rhys.morgan@sussex.ac.uk
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The aim of the project is to increase understanding of the role of cancer−associated abnormalities in the disruption of normal blood cell development. This information will be used to help devise treatment strategies designed to antagonise their effects. As a source of normal blood cell progenitors, we will make use of neonatal cord blood. This material is normally discarded together with other after−birth tissue and so can be obtained without any intervention to patient care.
We hope to identify new ways of treating blood cancer by targeting the disease−causing changes that arise in these conditions. A vital part of this work is to understand how normal blood cells grow and develop and the effect disease−causing changes can have. This is where cord blood cells are useful. By studying these cells in the laboratory we can learn a lot about how diseases such as leukaemia arise and so how they might be better treated.
Blood cancers are a group of diseases that affect young and old alike. Though chemotherapeutic drugs can be successfully used to treat these conditions, they have long−term side effects in the young and many elderly patients are unable to tolerate such aggressive treatment. Furthermore, patients may relapse with their disease many years after treatment. We hope to identify new and robust ways of treating these diseases by targeting the cancer−associated changes that arise in these malignancies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
If known, we would avoid consenting mothers with the following: - HIV, Hep B positive or having other serious medical conditions - Rhesus negative blood group - Under the legal age of consent - Learning difficulties - Poor understanding of English language - Already enrolled in a private cord blood banking arrangement
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Sussex and funded by THE KAY KENDALL LEUKAEMIA FUND .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 40742
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
